CDK11A

Summary

CDK11A (cyclin dependent kinase 11A, HGNC:1730) is a protein-coding gene on chromosome 1p36.33, encoding Cyclin-dependent kinase 11A (Q9UQ88). Cyclin-dependent protein kinase that acts as a regulator of transcription and pre-mRNA splicing. It is a selective cancer dependency (DepMap: 20.0% of cell lines).

This gene encodes a member of the serine/threonine protein kinase family. Members of this kinase family are known to be essential for eukaryotic cell cycle control. Due to a segmental duplication, this gene shares very high sequence identity with a neighboring gene. These two genes are frequently deleted or altered in neuroblastoma. The protein kinase encoded by this gene can be cleaved by caspases and may play a role in cell apoptosis. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 728642 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 138 total
• Druggable target: yes — 10 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 20.0% of screened cell lines
• MANE Select transcript: NM_024011

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1730
Approved symbol	CDK11A
Name	cyclin dependent kinase 11A
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Aliases	PITSLRE, CDK11-p110, CDK11-p58, CDK11-p46, p58GTA
Ensembl gene	ENSG00000008128
Ensembl biotype	protein_coding
OMIM	116951
Entrez	728642

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 14 protein_coding, 12 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000356200, ENST00000356937, ENST00000357760, ENST00000358779, ENST00000378633, ENST00000378638, ENST00000401096, ENST00000404249, ENST00000460465, ENST00000463652, ENST00000464748, ENST00000468397, ENST00000468800, ENST00000474916, ENST00000478901, ENST00000479362, ENST00000487462, ENST00000489300, ENST00000491311, ENST00000492390, ENST00000495016, ENST00000498810, ENST00000509982, ENST00000893735, ENST00000893736, ENST00000893737, ENST00000893738, ENST00000893739, ENST00000937803

RefSeq mRNA: 4 — MANE Select: NM_024011 NM_001313896, NM_001313982, NM_024011, NM_033529

CCDS: CCDS44042, CCDS44043, CCDS81253, CCDS81254

Canonical transcript exons

ENST00000404249 — 20 exons

Exon	Start	End
ENSE00001714517	1719328	1719455
ENSE00003466910	1712264	1712400
ENSE00003476013	1704039	1704146
ENSE00003484918	1705642	1705732
ENSE00003490604	1708180	1708245
ENSE00003493098	1709038	1709133
ENSE00003507378	1703824	1703940
ENSE00003525046	1721596	1721711
ENSE00003532668	1709518	1709640
ENSE00003538477	1704223	1704344
ENSE00003540484	1708794	1708952
ENSE00003563203	1722708	1722831
ENSE00003573320	1707409	1707584
ENSE00003629837	1704550	1704655
ENSE00003646560	1703080	1703269
ENSE00003647264	1716346	1716478
ENSE00003652156	1703476	1703624
ENSE00003673770	1704904	1705025
ENSE00003845610	1702379	1702999
ENSE00003850628	1724258	1724357

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.8482 / max 370.1381, expressed in 1809 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9817	22.3811	1806
9818	1.4671	879

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.32	gold quality
mucosa of transverse colon	UBERON:0004991	97.59	gold quality
granulocyte	CL:0000094	97.44	gold quality
spleen	UBERON:0002106	97.15	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.95	gold quality
small intestine	UBERON:0002108	96.44	gold quality
lower esophagus mucosa	UBERON:0035834	96.21	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.06	gold quality
pituitary gland	UBERON:0000007	96.01	gold quality
transverse colon	UBERON:0001157	95.97	gold quality
fundus of stomach	UBERON:0001160	95.93	gold quality
cerebellar hemisphere	UBERON:0002245	95.91	gold quality
cerebellum	UBERON:0002037	95.83	gold quality
cerebellar cortex	UBERON:0002129	95.83	gold quality
right lung	UBERON:0002167	95.80	gold quality
right lobe of thyroid gland	UBERON:0001119	95.49	gold quality
right testis	UBERON:0004534	95.46	gold quality
body of stomach	UBERON:0001161	95.38	gold quality
left testis	UBERON:0004533	95.37	gold quality
mucosa of stomach	UBERON:0001199	95.31	gold quality
upper lobe of left lung	UBERON:0008952	95.31	gold quality
bone marrow	UBERON:0002371	95.27	gold quality
left ovary	UBERON:0002119	95.15	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.15	gold quality
left lobe of thyroid gland	UBERON:0001120	95.12	gold quality
blood	UBERON:0000178	95.11	gold quality
apex of heart	UBERON:0002098	95.09	gold quality
metanephros cortex	UBERON:0010533	95.09	gold quality
body of uterus	UBERON:0009853	94.95	gold quality
intestine	UBERON:0000160	94.93	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.09
E-MTAB-8271	no	203.49
E-MTAB-8559	no	188.83
E-CURD-112	no	2.51

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1, ETS1

miRNA regulators (miRDB)

20 targeting CDK11A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-6830-5P	99.01	68.73	1884
HSA-MIR-4671-5P	97.10	65.70	93
HSA-MIR-7847-3P	96.63	64.58	952

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 20.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 15)

• demonstrates that CDK11(p46) directly interacts with RanBPM in vitro and in human cells (PMID:14511641)
• the PITSLRE IRES interacts with the Unr protein, which is more prominently expressed at the G2/M stage of the cell cycle (PMID:15330758)
• CDK11 kinases could be regulated by interaction with 14-3-3 proteins during cell cycle and apoptosis (PMID:15883043)
• CDK11(p58) is a new interacting protein and a novel regulator of histone acetyltransferase (HAT) HBO1. (PMID:15963510)
• CDK11p60 can contribute to apoptosis by direct signalling at the mitochondria, thereby amplifying Fas-induced apoptosis in melanoma cells. (PMID:16004605)
• These findings suggest that CDK11 may contribute to apoptosis by regulating the activity of NOT2 independent of its kinase activity. (PMID:16039607)
• mitotic CDK11(p58) isoform, but not the CDK11(p110) isoform, associates with mitotic centrosomes (PMID:16462731)
• CDC2L2 gene may contribute to the susceptibility of type 2 diabetes in the northern Han Chinese population. (PMID:17177267)
• findings show that, in addition to playing a role in spindle formation and structure, CDK11(p58) is also required for sister chromatid cohesion and the completion of mitosis (PMID:17606997)
• These data identified a new negative regulatory protein of ERalpha and provided a new pathway by which CDK11(p58) negatively regulated cells. (PMID:19122208)
• Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. (PMID:19245811)
• study identified p21 activated kinase 1 (PAK1) as a new CDK11(p58) substrate; mapped a new phosphorylation site of Ser174 on PAK1; results indicated PAK1 may serve as a downstream effector of CDK11(p58) during mitosis progression (PMID:19520772)
• CDK11 has a role in human cancers [review] (PMID:27049727)
• These results provided evidence that CDK11(p110) play a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells, which suggests that CDK11(p110) may be a promising therapeutic target in esophageal squamous cell carcinoma. (PMID:30722725)
• Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11(p110). (PMID:33309857)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdk11b	ENSDARG00000102546
mus_musculus	Cdk11b	ENSMUSG00000029062
rattus_norvegicus	AABR07040938.1	ENSRNOG00000005402
rattus_norvegicus	Cdk11b	ENSRNOG00000017213
drosophila_melanogaster	Pitslre	FBGN0016696

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK14 (ENSG00000058091), CDK17 (ENSG00000059758), CDK13 (ENSG00000065883), CDKL1 (ENSG00000100490), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Protein

Protein identifiers

Cyclin-dependent kinase 11A — Q9UQ88 (reviewed: Q9UQ88)

Alternative names: Cell division cycle 2-like protein kinase 2, Cell division protein kinase 11A, Galactosyltransferase-associated protein kinase p58/GTA, PITSLRE serine/threonine-protein kinase CDC2L2

All UniProt accessions (7): Q9UQ88, E7ESP2, E9PFJ2, J3KS35, Q5QPQ9, Q5QPR3, Q5QPR4

UniProt curated annotations — full annotation on UniProt →

Function. Cyclin-dependent protein kinase that acts as a regulator of transcription and pre-mRNA splicing. Acts as a key regulator of pre-mRNA splicing by mediating phosphorylation of SF3B1, enabling the association between SF3B1 and U5 and U6 snRNAs in the activated spliceosome, thereby promoting spliceosome assembly. Also acts as a regulator of transcription by phosphorylating ‘Ser-2’ of the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A. Involved in replication-dependent transcription of histone genes: binds to histone genes and phosphorylates POLR2A at ‘Ser-2’ of the CTD to specifically control transcriptional elongation of histones and recruitment of 3’-end processing factors. Part of a transcription checkpoint upstream of CDK9, which regulates promoter-proximal pausing by RNA polymerase II, a transcription halt following transcription initiation, but prior to elongation. Probably regulates promoter-proximal pausing by mediating phosphorylation of POLR2A at ‘Ser-2’ of the CTD. Isoform expressed in a non-cell cycle-dependent manner. Isoform specifically expressed during the G2-M phases of the cell cycle. Phosphorylates ‘Ser-2’ of the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A. Promotes centromeric transcription to maintain centromeric cohesion during mitosis.

Subunit / interactions. Associates with cyclin-L1 (CCNL1) or cyclin-L2 (CCNL2) to form an active cyclin-L-CDK11 cyclin-dependent protein kinase complex. Interacts with SAP30BP; promoting assenbly of the cyclin-L-CDK11 cyclin-dependent protein kinase complex. Interacts with CASP8AP2/FLASH; promoting 3’ end cleavage of histone pre-mRNAs. Associates with cyclin-L1 (CCNL1) or cyclin-L2 (CCNL2) to form an active cyclin-L-CDK11 cyclin-dependent protein kinase complex. Interacts with SFRS7. The cleaved p110 isoform, p110C, binds to the serine/threonine kinase PAK1. Associates with cyclin-D3 (CCND3) to form an active cyclin-dependent protein kinase complex.

Subcellular location. Nucleus. Chromosome. Cytoplasm Nucleus Nucleus. Centromere.

Tissue specificity. Expressed ubiquitously.

Post-translational modifications. During apoptosis, induced by Fas or tumor necrosis factor, specific CKD11 p110 isoforms are cleaved by caspases to produce a protein (p110C) that contains the C-terminal kinase domain of the CDK11 proteins.

Activity regulation. Phosphorylation at Thr-436 or Tyr-437 inactivates the enzyme, while phosphorylation at Thr-583 activates it. CDK11 (CDK11A and/or CDK11B) is specifically inhibited by the anticancer agent OTS964.

Induction. Specifically induced in G2/M phase of the cell cycle.

Miscellaneous. Duplicated gene. CDK11A and CDK11B encode almost identical protein kinases of 110 kDa that contain at their C-termini the open reading frame of a smaller 58 kDa isoform which is expressed following IRES-mediated alternative initiation of translation. Many references talk about ‘p110 isoforms’ but it is not yet known if this refers to CDK11A and/or CDK11B or one/some of the isoforms of each. Produced by alternative initiation at Met-345 of isoform SV6.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (8)

UniProt ID	Names	Canonical?
Q9UQ88-1	SV6, p110	yes
Q9UQ88-2	SV1, Pbeta21, Beta 2-1
Q9UQ88-3	SV2, Pbeta22
Q9UQ88-4	SV3
Q9UQ88-5	SV7, SV8
Q9UQ88-8	SV12
Q9UQ88-9	SV13
Q9UQ88-10	4, Beta 1, p58

RefSeq proteins (4): NP_001300825, NP_001300911, NP_076916, NP_277071 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR045267	CDK11/PITSLRE_STKc	Domain
IPR050108	CDK	Family

Pfam: PF00069

Catalyzed reactions (Rhea), 3 shown:

• [DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed RNA polymerase] + ADP + H(+) (RHEA:10216)
• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (53 total): modified residue 12, splice variant 11, sequence conflict 10, compositionally biased region 8, sequence variant 5, binding site 2, region of interest 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQ88-F1	66.94	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 550 (proton acceptor)

Ligand- & substrate-binding residues (2): 432–440; 455

Post-translational modifications (12): 47, 72, 271, 436, 437, 470, 476, 577, 582, 583, 739, 740

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes
R-HSA-1640170	Cell Cycle
R-HSA-380287	Centrosome maturation
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 152 (showing top): MORF_DNMT1, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, MODULE_255, GOBP_GROWTH, MODULE_317, MORF_HDAC2, NKX61_01, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CENTROSOME_CYCLE, MORF_RFC4, GOBP_RNA_SPLICING, HP1SITEFACTOR_Q6, MORF_PRKDC, GOBP_MITOTIC_CELL_CYCLE, BIOCARTA_HIVNEF_PATHWAY

GO Biological Process (10): mitotic cell cycle (GO:0000278), regulation of cell growth (GO:0001558), regulation of DNA-templated transcription (GO:0006355), protein phosphorylation (GO:0006468), apoptotic process (GO:0006915), regulation of apoptotic process (GO:0042981), regulation of RNA splicing (GO:0043484), regulation of centrosome cycle (GO:0046605), regulation of mRNA processing (GO:0050684), regulation of cell cycle (GO:0051726)

GO Molecular Function (9): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Centrosome maturation	1
G2/M Transition	1
Cell Cycle, Mitotic	1
Mitotic G2-G2/M phases	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell cycle	2
regulation of cellular component organization	2
regulation of gene expression	2
protein kinase activity	2
mitotic nuclear division	1
cell growth	1
regulation of growth	1
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
phosphorylation	1
protein modification process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
apoptotic process	1
regulation of programmed cell death	1
RNA splicing	1
regulation of primary metabolic process	1
centrosome cycle	1
regulation of cell cycle process	1
regulation of microtubule-based process	1
mRNA processing	1
regulation of mRNA metabolic process	1
regulation of cellular process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein serine/threonine kinase activity	1
cyclin-dependent protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
serine/threonine protein kinase complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2229 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDK11A	CCNL1	Q9UK58	901
CDK11A	MMP23B	O75900	861
CDK11A	RNPS1	Q15287	782
CDK11A	MMP21	Q8N119	767
CDK11A	CCNL2	Q96S94	766
CDK11A	SRSF7	Q16629	605
CDK11A	SRSF2	Q01130	586
CDK11A	SFN	P31947	515
CDK11A	CSDE1	O75534	495
CDK11A	CKAP5	Q14008	485
CDK11A	EIF4B	P23588	467
CDK11A	H1-0	P07305	451
CDK11A	TRIM25	Q14258	428
CDK11A	RAD17	O75943	417
CDK11A	AACS	Q86V21	410

IntAct

64 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
COMMD4	VPS26C	psi-mi:“MI:0914”(association)	0.730
HSP90AA1	CHUK	psi-mi:“MI:0914”(association)	0.670
FKBP5	IKBKB	psi-mi:“MI:0914”(association)	0.640
YWHAE	RGS12	psi-mi:“MI:0914”(association)	0.610
CHEK2	PPM1G	psi-mi:“MI:0914”(association)	0.560
YWHAE	SRSF10	psi-mi:“MI:0914”(association)	0.560
HSP90AB1	CDK11A	psi-mi:“MI:0915”(physical association)	0.560
CDK11A	HSP90AA1	psi-mi:“MI:0914”(association)	0.530
CCNL1	CDK11B	psi-mi:“MI:0914”(association)	0.530
HSPB8	VWA8	psi-mi:“MI:0914”(association)	0.530
Dlg4	CDK11A	psi-mi:“MI:0407”(direct interaction)	0.440
GADD45A	CDK11A	psi-mi:“MI:0915”(physical association)	0.370
CSNK2A1	MYO1B	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
BCAR1	CEP290	psi-mi:“MI:0914”(association)	0.350
PDHA1		psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
HTRA4	PSMD12	psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	EIF3F	psi-mi:“MI:0914”(association)	0.350
CDK11A	APOA1	psi-mi:“MI:0914”(association)	0.350
HSP90AA1	URI1	psi-mi:“MI:0914”(association)	0.350
	HLA-C	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	VWA8	psi-mi:“MI:0914”(association)	0.350

BioGRID (245): CDK11A (Affinity Capture-MS), WDR47 (Affinity Capture-MS), DDB2 (Affinity Capture-MS), CDK11B (Affinity Capture-MS), ZG16B (Affinity Capture-MS), C12orf43 (Affinity Capture-MS), SPRR3 (Affinity Capture-MS), CRNN (Affinity Capture-MS), AP3B1 (Co-fractionation), CTR9 (Co-fractionation), DPF2 (Co-fractionation), LEO1 (Co-fractionation), NOLC1 (Co-fractionation), PELP1 (Co-fractionation), SAP30BP (Co-fractionation)

ESM2 similar proteins: A2X6X1, A2XUW1, A9RVK2, B9FMJ3, F4HRJ4, F4I114, F4ICB6, O08678, O08679, O45818, P21127, P24788, P27448, P78362, Q03141, Q05512, Q08DZ2, Q09437, Q13523, Q23357, Q39008, Q40541, Q5R814, Q5RKH1, Q5Z9J0, Q5ZCI1, Q61136, Q6K5F8, Q6L5D4, Q6L5F7, Q6Z829, Q7KZI7, Q7XUF4, Q8H0U8, Q8RX66, Q8VHF0, Q8VHJ5, Q96VK3, Q9C9U4, Q9C9U5

Diamond homologs: A1CL96, A1D624, A2QU77, A2X6X1, A2XUW1, A3LUB9, A4QXX4, A8XA58, O13958, O55076, O61847, O96821, P00546, P06493, P0C661, P0CS76, P0CS77, P11440, P21127, P23111, P23437, P23572, P24033, P24100, P24788, P24923, P24941, P29618, P29619, P34112, P34117, P34556, P35567, P39073, P39951, P43063, P43450, P46892, P48734, P48963

SIGNOR signaling

9 interactions.

A	Effect	B	Mechanism
CDK11A	up-regulates	CDK11B	phosphorylation
CDK11A	“down-regulates quantity by destabilization”	SPDEF	phosphorylation
GADD45A	“down-regulates activity”	CDK11A	binding
GADD45B	“down-regulates activity”	CDK11A	binding
GADD45G	“down-regulates activity”	CDK11A	binding
CDK11A	“up-regulates activity”	PAK1	phosphorylation
CDK11A	“form complex”	CyclinD3/CDK11A	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 84 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Orc1 removal from chromatin	5	13.9×	2e-03
G2/M Checkpoints	6	12.6×	1e-03
Assembly of the pre-replicative complex	5	10.9×	2e-03
ESR-mediated signaling	5	10.0×	2e-03
SARS-CoV-2 activates/modulates innate and adaptive immune responses	5	7.0×	7e-03
Cell Cycle Checkpoints	5	6.9×	7e-03
Cell Cycle, Mitotic	8	6.0×	2e-03
Cellular responses to stress	8	4.6×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	25.7×	3e-04
protein stabilization	8	6.9×	2e-03
regulation of cell cycle	7	6.7×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

138 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	120
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3169 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1703474:A:AC	donor_gain	1.0000
1:1703475:C:CC	donor_gain	1.0000
1:1703622:CTC:C	acceptor_gain	1.0000
1:1703623:TCCTG:T	acceptor_loss	1.0000
1:1703624:CCT:C	acceptor_loss	1.0000
1:1703625:C:CC	acceptor_gain	1.0000
1:1703626:T:A	acceptor_loss	1.0000
1:1703819:CCCA:C	donor_loss	1.0000
1:1703820:CCACC:C	donor_loss	1.0000
1:1703938:TTCCT:T	acceptor_loss	1.0000
1:1703939:TCCT:T	acceptor_loss	1.0000
1:1703940:CCTA:C	acceptor_loss	1.0000
1:1703941:C:CC	acceptor_gain	1.0000
1:1703941:CTAAG:C	acceptor_loss	1.0000
1:1703942:T:G	acceptor_loss	1.0000
1:1704034:CTCA:C	donor_loss	1.0000
1:1704035:TCA:T	donor_loss	1.0000
1:1704036:CA:C	donor_loss	1.0000
1:1704037:A:AC	donor_gain	1.0000
1:1704038:C:CC	donor_gain	1.0000
1:1704038:C:CT	donor_loss	1.0000
1:1704142:CCCAC:C	acceptor_gain	1.0000
1:1704143:CCAC:C	acceptor_gain	1.0000
1:1704143:CCACC:C	acceptor_gain	1.0000
1:1704144:CAC:C	acceptor_gain	1.0000
1:1704144:CACC:C	acceptor_gain	1.0000
1:1704145:AC:A	acceptor_gain	1.0000
1:1704145:ACCTG:A	acceptor_loss	1.0000
1:1704146:CC:C	acceptor_gain	1.0000
1:1704147:C:CA	acceptor_loss	1.0000

AlphaMissense

5167 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1702917:A:T	L781H	1.000
1:1702922:G:C	F779L	1.000
1:1702922:G:T	F779L	1.000
1:1702923:A:G	F779S	1.000
1:1702924:A:G	F779L	1.000
1:1704272:C:G	R549P	1.000
1:1704296:A:G	L541P	1.000
1:1704624:A:C	I500S	1.000
1:1704624:A:T	I500N	1.000
1:1704642:C:A	G494V	1.000
1:1704642:C:T	G494D	1.000
1:1704643:C:A	G494C	1.000
1:1704643:C:G	G494R	1.000
1:1704645:A:T	V493E	1.000
1:1704648:A:T	V492E	1.000
1:1704959:A:G	L471P	1.000
1:1704973:G:C	F466L	1.000
1:1704973:G:T	F466L	1.000
1:1704974:A:C	F466C	1.000
1:1704974:A:G	F466S	1.000
1:1704975:A:G	F466L	1.000
1:1704978:C:G	G465R	1.000
1:1705001:A:G	L457P	1.000
1:1705001:A:T	L457Q	1.000
1:1705006:C:A	K455N	1.000
1:1705006:C:G	K455N	1.000
1:1705010:A:G	L454P	1.000
1:1705010:A:T	L454Q	1.000
1:1705709:G:C	F426L	1.000
1:1705709:G:T	F426L	1.000

dbSNP variants (sampled 300 via entrez): RS1000740395 (1:1714741 A>T), RS1001223299 (1:1702242 C>G,T), RS1001388900 (1:1720260 A>G), RS1001407908 (1:1710294 C>G,T), RS1001418649 (1:1720034 G>C), RS1001692248 (1:1710691 G>A), RS1001797386 (1:1703360 T>C), RS1001951364 (1:1725963 T>C), RS1002295137 (1:1707992 C>T), RS1002382689 (1:1725218 G>A), RS1002849032 (1:1719013 T>C), RS1002949405 (1:1724307 G>A,C), RS1002982109 (1:1724042 T>C), RS1003251104 (1:1706625 C>T), RS1003367300 (1:1706429 G>A)

Disease associations

OMIM: gene MIM:116951 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_34	Body mass index	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL5416 (SINGLE PROTEIN), CHEMBL5483187 (PROTEIN COMPLEX), CHEMBL6066064 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

10 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 45,567 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL215152	DEFOSBARASERTIB	2	372
CHEMBL384304	RG-547	2	93
CHEMBL445813	AT-7519	2	2,614
CHEMBL572878	TOZASERTIB	2	2,998
CHEMBL296468	BMS-387032	1	2,075
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — PITSLRE subfamily

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methyl-phenyl)urea	KD	450 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
BMS-387072	KD	1800 nM
2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}-N-(3-fluorophenyl)acetamide	KD	1900 nM
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide	KD	2900 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM

ChEMBL bioactivities

75 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	IC50	1.7	nM	CHEMBL4455382
8.28	Kd	5.2	nM	AT-7519
7.48	Kd	33	nM	CHEMBL1989043
7.42	Kd	38	nM	CHEMBL5185990
7.41	Kd	39	nM	CHEMBL5175800
7.37	Kd	43	nM	CHEMBL5185655
7.32	Kd	48	nM	BMS-387032
7.31	Kd	49	nM	CHEMBL5200963
7.16	Kd	69	nM	CHEMBL5180190
7.00	Kd	99	nM	CHEMBL5184522
6.96	Kd	110	nM	JNJ-7706621
6.89	Kd	130	nM	CHEMBL5206282
6.85	Kd	140	nM	CHEMBL5170651
6.82	Kd	150	nM	CHEMBL5182610
6.77	Kd	170	nM	CHEMBL5171843
6.77	IC50	170	nM	CHEMBL1989043
6.72	IC50	190	nM	CHEMBL5175800
6.64	IC50	230	nM	CHEMBL5185990
6.64	IC50	230	nM	CHEMBL5180190
6.58	IC50	260	nM	CHEMBL5185655
6.58	Kd	260	nM	TOZASERTIB
6.54	Kd	290	nM	CHEMBL5208491
6.48	Kd	330	nM	CHEMBL5200790
6.48	IC50	330	nM	CHEMBL5206282
6.43	Kd	370	nM	CHEMBL4553037
6.41	Kd	390	nM	BMS-345541
6.40	Kd	399	nM	CHEMBL4799297
6.39	Kd	410	nM	CHEMBL5180851
6.38	Kd	420	nM	CRIZOTINIB
6.33	IC50	470	nM	CHEMBL5200790
6.32	Kd	480	nM	FORETINIB
6.24	Kd	570	nM	CHEMBL5207135
6.24	IC50	580	nM	CHEMBL5208491
6.21	IC50	620	nM	CHEMBL5173236
6.16	Kd	690	nM	CHEMBL5199067
6.16	IC50	700	nM	CHEMBL5200963
6.15	IC50	710	nM	CHEMBL5184522
6.10	IC50	800	nM	CHEMBL5182610
6.05	IC50	900	nM	CHEMBL5171843
6.02	Kd	960	nM	CHEMBL5180130
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
6.00	Kd	1000	nM	CHEMBL5180577
6.00	IC50	1000	nM	CHEMBL5194816
6.00	Kd	1000	nM	DEFOSBARASERTIB
5.96	Kd	1100	nM	CHEMBL5169674
5.96	Kd	1100	nM	AST-487
5.92	IC50	1200	nM	CHEMBL5180130
5.92	IC50	1200	nM	CHEMBL5203750

PubChem BioAssay actives

66 with measured affinity, of 219 total; 42 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	625133: Binding constant for CDC2L2 kinase domain	kd	0.0052	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0330	uM
[4-amino-2-[[6-(4-methylpiperazin-1-yl)-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0380	uM
[4-amino-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0390	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-difluorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0430	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	435649: Binding constant for CDC2L2 kinase domain	kd	0.0480	uM
[4-amino-2-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0490	uM
[4-amino-2-[[2-methyl-6-(4-methylpiperazin-1-yl)-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0690	uM
[4-amino-2-[3-methoxy-4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.0990	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435649: Binding constant for CDC2L2 kinase domain	kd	0.1100	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2-chlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.1300	uM
[4-[[4-amino-5-(2,6-dichlorobenzoyl)-1,3-thiazol-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.1400	uM
[4-amino-2-[2-methyl-4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.1500	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-[2-fluoro-6-(trifluoromethyl)phenyl]methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.1700	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	435649: Binding constant for CDC2L2 kinase domain	kd	0.2600	uM
[4-amino-2-[[4-methyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.2900	uM
[4-amino-2-[[3-methyl-5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.3300	uM
N’-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine	625133: Binding constant for CDC2L2 kinase domain	kd	0.3900	uM
[4-amino-2-[3-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.4100	uM
Crizotinib	625133: Binding constant for CDC2L2 kinase domain	kd	0.4200	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	625133: Binding constant for CDC2L2 kinase domain	kd	0.4800	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-[(2S,6R)-2,6-dimethylpiperidin-1-yl]methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.5700	uM
[4-amino-2-[[6-(2,4-dimethylpiperazin-1-yl)-2-methyl-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	0.6200	uM
[4-amino-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.6900	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)sulfonylanilino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	0.9600	uM
2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide	435649: Binding constant for CDC2L2 kinase domain	kd	1.0000	uM
N-[5-(2,6-dichlorobenzoyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-4-yl]acetamide	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	1.0000	uM
[4-amino-2-[[2-methyl-6-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	1.0000	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435649: Binding constant for CDC2L2 kinase domain	kd	1.1000	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3-chloro-2-pyridinyl)methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	1.1000	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	435649: Binding constant for CDC2L2 kinase domain	kd	1.2000	uM
[4-amino-2-[(2-methyl-6-piperazin-1-yl-3-pyridinyl)amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	1.2000	uM
Pazopanib	435649: Binding constant for CDC2L2 kinase domain	kd	1.3000	uM
[4-amino-2-[[2-methyl-6-(4-methyl-3-propan-2-ylpiperazin-1-yl)-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	1.5000	uM
[4-amino-2-[[6-(4-hydroxypiperidin-1-yl)-2-methyl-3-pyridinyl]amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	2.2000	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769528: Binding affinity to CDC2L2 (unknown origin)	kd	2.4000	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	625133: Binding constant for CDC2L2 kinase domain	kd	2.9000	uM
[4-amino-2-[(2-methyl-6-morpholin-4-yl-3-pyridinyl)amino]-1,3-thiazol-5-yl]-(2,6-dichlorophenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	3.4000	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-phenylmethanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	4.2000	uM
(2,6-dichlorophenyl)-[4-(methylamino)-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]methanone	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	4.8000	uM
4-amino-N-(2,6-dichlorophenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazole-5-carboxamide	1860788: Binding affinity to wild type human partial length CDK11A (D391 to K730 residues) expressed in bacterial expression system assessed as dissociation constant by KdELECT assay	kd	4.8000	uM
[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,4,6-trimethylphenyl)methanone	1860789: Inhibition of N-terminus or C-terminus NLuc fused CDK11A (unknown origin) transfected in HEK293 cells by NanoBRET assay	ic50	6.1000	uM

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	increases expression, affects cotreatment, decreases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	affects cotreatment, decreases expression	1
cobaltous chloride	increases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
licochalcone B	increases expression	1
Ascorbic Acid	affects cotreatment, increases expression	1
Formaldehyde	increases expression	1
Silicon Dioxide	decreases expression	1
Valproic Acid	increases methylation	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	increases expression	1
Acrylamide	increases expression	1
Chlorodiphenyl (54% Chlorine)	increases expression	1
Particulate Matter	increases expression	1

ChEMBL screening assays

111 unique, capped per target: 111 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1032228	Binding	Inhibition of CDC2L2 at 3 uM	Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. — J Med Chem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2U0	Abcam HEK293T CDK11A KO	Transformed cell line	Female
CVCL_SI20	HAP1 CDK11A (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.